DOXLIEVA 50MG ( Doxorubicin Hydrochloride iInjection IP 50mg )

DOXLIEVA 50 mg contains Doxorubicin Hydrochloride, an anthracycline antitumor antibiotic. It acts by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis of cancer cells. It is a backbone drug in many chemotherapy regimens.

Doxorubicin is indicated for treatment of:

1. Breast Cancer

2. Lymphomas (Hodgkin’s and Non-Hodgkin’s)

3. Leukemias (ALL, AML)

4. Soft Tissue & Bone Sarcomas

5. Ovarian Cancer

6. Bladder Cancer

7. Multiple Myeloma

Common side effects:

•  Myelosuppression

•  Nausea, vomiting

•  Alopecia

•  Mucositis

Important dose-limiting toxicity:

•  Cardiotoxicity (acute arrhythmias, chronic cardiomyopathy)

Other side effects:

•  Red discoloration of urine

•  Extravasation injury (vesicant)

 Monitor LVEF / echocardiography and cumulative dose.

Dosage depends on regimen and patient condition.

Typical dosing:

•  60–75 mg/m² IV every 21 days
    or

•  20–30 mg/m² IV weekly

Maximum cumulative dose: ~450–550 mg/m²


NOTE: This medicine should be taken only under a doctor’s supervision.